ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CCR8 Antibody-drug Conjugate TAK-188

Its studies are led by Takeda.

Furthest: phase 2, since Sep 26, 20251 company-led study, 1 open or runningNext primary completion: Dec 26, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda11 open or runningphase 2since Sep 26, 2025Sep 26, 2025Dec 26, 2028phase 2 · NCT07205718

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 26, 2025First study: phase 2 study in Advanced or Metastatic Solid TumorsFirst studyNCT07205718 · 273 planned · United States

Ahead

  1. Dec 26, 2028Primary completion: phase 2 study in Advanced or Metastatic Solid TumorsNCT07205718

TargetBeta

CCR8 →read by rule
“An antibody-drug conjugate (ADC) composed of an antibody directed against human C-C motif chemokine receptor 8 (CCR8) ”NCIt, by rule

Other programs on CCR8

ProgramCompanyFurthest phaseStudies
cafelkibartSino Biopharmaceuticalphase 37
CCR8 Inhibitor IPG7236rulenanjing-immunophage-biotech-co-ltdphase 23
denikitugruleGilead Sciencesphase 23
tagmokitugrulecoherus-oncology-incphase 23
imzokitugBristol-Myers Squibbphase 22
Anti-CCR8 Monoclonal Antibody HC006rulehc-biopharma-incphase 12
azirkitugAbbViephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07205718Advanced or Metastatic Solid Tumors · United States2RecruitingDec 26, 2028273

How it is read

Names in the registry

  • “TAK-188”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.